GlassScriptPhysician profile
Arman Saied
NPI 1689358426
$617.14
in general payments reported to CMS, 2019-2025
9 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $295 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $617.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $125.00 | 2024 | Rystiggo |
| Alexion Pharmaceuticals, INC. | $114.33 | 2024 | |
| Amgen INC. | $113.66 | 2025 | Uplizna |
| Janssen Biotech, INC. | $79.10 | 2025 | |
| Amneal Pharmaceuticals LLC | $69.16 | 2025 | Crexont |
| Emd Serono, INC. | $55.86 | 2024 | Mavenclad |
| Eisai INC. | $22.13 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $21.29 | 2025 | Wainua |
| Merz Pharmaceuticals, LLC | $16.61 | 2025 | Inbrija, Ampyra, Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arman Saied listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.